Beijing furuikangzheng class 3.1 new drug: the first approved clinical application
-
Last Update: 2015-01-20
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The class 3.1 new drug konivartan hydrochloride declared by Beijing furuikangzheng medicine was approved for clinical application on January 14, 2015, and its current status is "under approval" This is the first enterprise in China to be approved for clinical application among the seven enterprises applying for konivartan hydrochloride (injection and API) The original manufacturer of konivartan hydrochloride is Astaire pharmaceutical, which is a double antagonist of AVP V1a and V2 receptor It was approved by FDA as a treatment drug of positive volume hyponatremia in December 2005, and then by FDA in February 2007 Approved for treatment of hospitalized patients with positive and high volume hyponatremia (trade name: vaprisol) As a diuretic of antagonists accepted by AVP, konivartan has little market competition Only tovaptan (trade name: sumeka), a selective arginine vasopressin V2 receptor antagonist of Otsuka pharmaceutical, has been approved for marketing in China Founded in 1998, Beijing Furui Kangzheng Pharmaceutical Technology Research Institute is a high-tech enterprise specializing in the research of chemicals, traditional Chinese medicine, natural drugs and health products.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
